Pfizer, GSK RSV shots for older adults may prevent thousands of hospitalizations, CDC analysis says

[ad_1] Respiratory syncytial virus vial. Manjurul | Istock | Getty Images Vaccinating one million adults ages 65 and above with a single RSV shot from Pfizer or GSK may prevent…

FDA advisors recommend that new Covid vaccines target an omicron XBB variant this fall

[ad_1] A woman receives a booster dose of the Moderna coronavirus disease (COVID-19) vaccine at a vaccination centre in Antwerp, Belgium, February 1, 2022. Johanna Geron | Reuters The U.S.…

Covid vaccine maker Novavax sees a pathway to survival – but it won’t be easy

[ad_1] Medical syringes and Novavax logo displayed in the background are seen in this illustration photo taken in Krakow, Poland on December 2, 2021. Jakub Porzycki | NurPhoto | Getty…

Startups’ Patch Technologies Could Extend Reach of Vaccines

[ad_1] In several countries the effort to eradicate measles runs into the logistical obstacle of insufficient cold storage for vaccines.    Patches from startups including Micron Biomedical and Vaxxas could overcome…

FDA approves GSK’s RSV vaccine for older adults, world’s first shot against virus

[ad_1] A GSK lab in London. Oli Scarff | Getty Images The Food and Drug Administration on Wednesday approved an RSV vaccine produced by GlaxoSmithKline for use on adults ages…

FDA Approves GSK’s RSV Vaccine for Older Adults

[ad_1] Health Approval of respiratory syncytial virus vaccine is a first for people 60 years and older, company says [ad_2] Source link

Government of Ontario Invests in Virica Biotech

[ad_1] Government of Ontario Invests in Virica Biotech | West Virginia …  WV News [ad_2] Source link

Single Dose of Omicron-Targeting Vaccines to Become Main Covid-19 Shot in U.S.

[ad_1] Health The FDA also authorized a second Omicron-targeting booster shot for high-risk groups [ad_2] Source link

Moderna, Merck Show Progress Toward Cancer Vaccines

[ad_1] An mRNA shot helped prevent relapse in high-risk melanoma patients. [ad_2] Source link

Moderna CEO Defends Pricing Plans for Covid-19 Shot

[ad_1] Stéphane Bancel said investors funded the mRNA vaccine platform. [ad_2] Source link